Kalamazoo Pride drew tens of thousands this year, despite fewer sponsors and a changing political landscape. The festival was ...

On May 13th, 1980, an F3 tornado traveled 11 miles from the west side of Kalamazoo through downtown before lifting near Comstock. Five people were killed and 79 were seriously injured. Bronson Park, ...

It's been a tough go for Pfizer (NYSE: PFE). Shares of the pharmaceutical giant are down over 60% from their highs, a multi-year slide since pandemic-related sales peaked a few years ago.

US drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc, paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones are met.

While Pfizer Ltd had reported Rs179 crore In the corresponding quarter of the previous fiscal, or March quarter of FY24, the net profit in the March 2025 quarter saw a sharp jump to ₹331 crore.

It did not take long for Pfizer Inc. (NYSE:PFE) to change its mind on its oncology pipeline approach – after the deal with Summit Therapeutics Inc. (SMMT) in February for co-development of ...

Shares of Pfizer jumped by as much as 11 percent to Rs 4,995 apiece on May 20 after the company posted a strong performance for the March quarter (Q4FY25). In the past month, this pharma stock ...

Pfizer Inc. plans to spend billions of dollars to join the race for a new type of cancer treatment. Similar to its competitors, Pfizer also plans to partner with a Chinese company. The company PFE ...

Pfizer's licensing deal with China's 3Sbio for PD-1/VEGF antibody has an upfront payment more than double what Merck paid last year for its deal with China's LaNova Pfizer Inc. plans to spend ...

Shares of Pfizer Ltd are in news today rose after the firm reported a stellar set of Q4 earnings. The pharma firm reported a 85% year-on-year (YoY) rise in net profit at Rs 331 crore for the ...

Emilio Parra Doiztua / Bloomberg / Getty Images Pfizer said late Monday that it has agreed to a deal to help develop and market a Chinese cancer drug across the globe. Chinese firm 3SBio is ...

Pfizer announces a licensing agreement with 3SBio to develop, manufacture and commercialize SSGJ-707 globally, excluding China. Ready to turn the market’s comeback into steady cash flow?